Beam Therapeutics (BEAM) Operating Leases (2019 - 2025)
Historic Operating Leases for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $138.7 million.
- Beam Therapeutics' Operating Leases fell 697.18% to $138.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.7 million, marking a year-over-year decrease of 697.18%. This contributed to the annual value of $148.0 million for FY2024, which is 747.6% down from last year.
- Beam Therapeutics' Operating Leases amounted to $138.7 million in Q3 2025, which was down 697.18% from $141.9 million recorded in Q2 2025.
- In the past 5 years, Beam Therapeutics' Operating Leases ranged from a high of $168.6 million in Q4 2022 and a low of $125.8 million during Q1 2021
- Over the past 5 years, Beam Therapeutics' median Operating Leases value was $149.1 million (recorded in 2024), while the average stood at $149.5 million.
- As far as peak fluctuations go, Beam Therapeutics' Operating Leases surged by 45909.28% in 2021, and later plummeted by 747.6% in 2024.
- Beam Therapeutics' Operating Leases (Quarter) stood at $134.8 million in 2021, then grew by 25.08% to $168.6 million in 2022, then fell by 5.17% to $159.9 million in 2023, then dropped by 7.48% to $148.0 million in 2024, then decreased by 6.23% to $138.7 million in 2025.
- Its Operating Leases stands at $138.7 million for Q3 2025, versus $141.9 million for Q2 2025 and $144.9 million for Q1 2025.